Table 2.
Concomitant antibiotic use over the period of 12 months prior to initiating ALIS
| ALIS cohort | |
|---|---|
| Antibiotic class/antibiotic | (N = 331) |
| GBT regimena | 74 (22.4) |
| Macrolide | 133 (40.2) |
| Azithromycin | 127 (38.4) |
| Clarithromycin | 16 (4.8) |
| Ethambutol | 83 (25.1) |
| Rifamycin | 87 (26.3) |
| Rifabutin | 13 (3.9) |
| Rifampin | 82 (24.8) |
| Aminoglycoside | 47 (14.2) |
| Amikacin sulfate | 39 (11.8) |
| Tobramycin | 14 (4.2) |
| Fluoroquinolone | 96 (29.0) |
| Ciprofloxacin | 50 (15.1) |
| Levofloxacin | 61 (18.4) |
| Moxifloxacin | 9 (2.7) |
| Other antibiotics classes | |
| Cephalosporin | 6 (1.8) |
| Carbapenem | 8 (2.4) |
| Oxazolidinone | 14 (4.2) |
| Glycylcycline | 5 (1.5) |
| Tetracycline | 37 (11.2) |
All data are presented as n (%)
ALIS amikacin liposome inhalation suspension, GBT guideline-based treatment
aGBT based on American Thoracic Society/European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases/Infectious Diseases Society of America clinical practice guidelines [23] guidelines refer to three-drug combination of a macrolide plus ethambutol with a third antibiotic, typically a rifamycin